Title variants
Languages of publication
Abstracts
Personalized medicine is coming step by step to real clinical practice. The new era is forthcoming, in which 'one size does not fit all'. The hopes and expectations predominantly are based on achievements of molecular biology. Close connection between therapy and corresponding diagnostic test can lead to better defining patients target groups. Moreover, biomarkers defining is becoming a new approach to therapy stratification. Viral, oncologic, inflammatory and metabolic diseases are the examples of Roche involvement in this strategic way of development.
Discipline
Journal
Year
Issue
Pages
84-87
Physical description
Contributors
author
author
References
Document Type
MONOGRAPHY
Publication order reference
Claudia Schmitt, Hoffmann-La Roche Ltd, Basel
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-7807f54d-51f1-3c1d-974a-609f4325f82d